Central Giant Cell Granuloma Surgery
On this page
Direct answer
A multilocular radiolucency crossing the midline of the anterior mandible in a young adult, with vital teeth and cortical expansion, is the textbook central giant cell granuloma (formerly "reparative" granuloma) — and its surgery begins, counterintuitively, in the blood laboratory, because hyperparathyroidism produces an identical lesion (the brown tumour) that is treated by the endocrinologist, not the surgeon. The genuine giant cell lesion is then stratified by behaviour: non-aggressive lesions are cured by thorough curettage with recurrence in a minority, while aggressive lesions — rapid growth, cortical perforation, root resorption, recurrence after treatment — justify wider resection or multimodal therapy. Intralesional corticosteroids, salmon calcitonin, interferon and denosumab have all been used to avoid mutilating surgery in children, and surgical results are guarded with radiographic surveillance.
What you must remember
- Profile: under 30 years, female predilection, anterior mandible foremost, frequently crossing the midline — the classic spotter clue; teeth vital, displaced more than resorbed.
- The endocrine gate: serum calcium, phosphate, alkaline phosphatase and parathyroid hormone exclude primary hyperparathyroidism, whose brown tumour is histologically indistinguishable — omitting this screen is the classic management error.
- Behavioural classification (Chuong and co-workers): aggressive — rapid growth, cortical perforation, root resorption, recurrence after curettage; non-aggressive — slow, expansile, low recurrence. The class, not histology, chooses the operation.
- Histology in one line: osteoclast-type multinucleated giant cells scattered in a fibroblastic stroma with haemosiderin, haemorrhage and osteoid — the same picture as brown tumour and cherubism, so the diagnosis is clinico-radiological-biochemical.
- Surgical ladder: non-aggressive — thorough curettage with peripheral ostectomy (some add chemical cautery or cryotherapy to the bed); aggressive, recurrent or enormous — en bloc resection with immediate reconstruction.
- Pharmacological alternatives worth quoting: intralesional triamcinolone injections over multiple sessions, subcutaneous or intranasal salmon calcitonin for months (child-friendly, slow), interferon alfa historically, and denosumab — a RANKL inhibitor — as the modern medical option, mindful of rebound and jaw osteonecrosis concerns on withdrawal.
- Recurrence figures: after simple curettage commonly quoted between roughly ten and thirty-five per cent, higher in the aggressive class — the justification for aggressive adjuncts and surveillance.
- Cherubism connection: bilateral multilocular lesions in a child with a family history and submandibular lymphadenopathy suggest cherubism (SH3BP2 mutation) — biopsy may be unnecessary and surgery minimised until quiescence.
From biopsy to the parathyroid screen
A 19-year-old woman has a nine-month expansion of the anterior mandible; the lower incisors are splayed but vital, the occlusal film shows a multilocular radiolucency thinning the cortex, and the lesion clearly crosses the midline. The first prescription is a laboratory form, not an operation list: calcium, phosphate, alkaline phosphatase and parathyroid hormone. Normal results clear the brown-tumour mimic; incisional biopsy returns giant cells in a fibrohaemorrhagic stroma.
Stratification follows. Her lesion has perforated the lingual cortex — aggressive class. One school offers thorough curettage with peripheral ostectomy and close radiographic follow-up; the other, in a young patient worried about deformity, combines curettage with adjuncts or precedes surgery with calcitonin or denosumab to shrink the lesion. Either pathway documents a calendar: films at six-month intervals for at least two years, because recurrence announces itself radiographically before it becomes clinical. The operation is sized to the behaviour, and the behaviour is named before the incision.
The recurrence and re-treatment question
Indian exam pattern note: this lesion appears both in oral pathology spotters and in oral surgery long questions, and the surgical answer must carry four anchors — the hyperparathyroid screen, the aggressive/non-aggressive divide, the recurrence percentage, and the named pharmacological alternatives. The viva follow-up is usually "it recurred after curettage — now what?", answered by a ladder: re-curettage with adjuncts (chemical cautery, cryotherapy) for a small recurrence; en bloc resection for an aggressive recurrence in a grown patient; calcitonin or denosumab where surgery would mutilate a child. Examiners also enjoy the three-way histological twin question — central giant cell granuloma, brown tumour and cherubism — expecting the answer that histology cannot separate them and that clinical, biochemical and genetic context does. A candidate who mentions hyperparathyroidism jaw disease (brown tumour regression after parathyroidectomy) has read beyond the syllabus, in the right direction.
Frequently asked questions
Which blood investigations must precede surgery for a giant cell lesion of the jaw?
Serum calcium, phosphate, alkaline phosphatase and parathyroid hormone, to exclude primary hyperparathyroidism whose brown tumour is histologically identical.
How are central giant cell lesions classified behaviourally?
Into non-aggressive (slow, expansile, low recurrence) and aggressive (rapid growth, cortical perforation, root resorption, recurrence after treatment) classes that dictate surgical extent.
What is the standard surgical treatment and its recurrence risk?
Thorough curettage with peripheral ostectomy for non-aggressive disease, with recurrence commonly quoted between about ten and thirty-five per cent, higher in aggressive lesions.
Which non-surgical options exist for aggressive lesions in children?
Intralesional triamcinolone, long-course salmon calcitonin, interferon alfa historically, and denosumab as the modern RANKL-inhibitor option, each with monitoring.
What is cherubism and how does it mimic this lesion?
An SH3BP2-mutation familial disorder of childhood producing bilateral multilocular giant cell lesions of the jaws, managed expectantly until quiescence rather than by aggressive surgery.